Reading Time: 6 minutes On 29th September 2022 AMX0035, a treatment for Motor Neurone Disease (MND) was approved by the Food and Drug Administration (FDA) in the United States.
Search Results for: amx0035
Reading Time: 5 minutes This blog is part of the ‘Virtual Highlights’ collection of articles, where you can read about the content of some of the talks and posters
Reading Time: 2 minutes This week saw the publication of the Phase 2/3 trial results of the experimental drug cocktail, AMX0035, developed by the pharmaceutical company, Amylyx, and carried
Reading Time: 5 minutes Building relationships with key research institutes across the UK is vital in pushing research forward in the fight against MND. As of 31 December 2023,
Reading Time: 7 minutes Hi, I’m Heather, a PhD student from King’s College London, and a Communications Ambassador for the 34th International Symposium on ALS/MND which was held in Basel last December. Over 1,300 attendees from around the world gathered to connect with researchers and people affected by MND and engage with the latest research presented in the platform presentation and poster sessions. In this blog post, I will be sharing several of my personal highlights of the symposium, which cover how differences in our genetic code can be explored to understand their effects on MND risk and progression.
Reading Time: 5 minutes "New drug reduces risk of death by 50%"
You may have seen this type of headline in news articles reporting on the outcome of clinical trials. Reading this headline can lead people to believe a potential drug is highly beneficial and has a real impact. However, it is important to delve a little deeper into the meaning of ‘risk of death’, the raw data behind it, and how it should be considered alongside other outcome measures of a trial to fully determine how effective a drug might be.
Reading Time: 4 minutes In our brains, specific areas control the movement of different body parts (see image below). As we know, MND is a complex disease with a lot of variation between individuals who are affected. For example, symptoms may start in different body parts for different individuals. Understanding why this happens may help us predict the disease onset site or progression across the body in the future.
Reading Time: 6 minutes Over the past couple of years, the pace of MND research has continued to increase. In the last year alone, we saw an increase in
Reading Time: 12 minutes Despite decades of research, we still do not fully understand why some people get MND, but studies in cell and animal models of the disease